On August 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that the newly developed humanized IgG1 CD70 antibody (project number: IMM40H) has been approved by the US FDA and China NMPA for Clinical trial research almost simultaneously.

On August 6, 2022, the Securities Times Biomedical Innovation Forum and the 2nd Drug Innovation Award Ceremony hosted by the Securities Times were held in Shanghai. Chairman founder of ImmuneOnco，Dr.Tian, Wenzhi,, was successfully selected as the "Top Ten Drug Innovation Scientists in 2021", and Drug candidate IMM2902 for Injection won the "Annual Drug Innovation Pioneering Award".

On June 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that SIRPaFc recombinant protein targeting human CD47 ，IMM01， combined with azacitidine (AZA) in the treatment of relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Phase Ib/II clinical study (clinical research project number: IMM01-02), completed the first patient enrollment for first dosing.

On June 20, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that, on June 20, local time, an FDA-registered Phase I clinical trial of the first globally novel bi-specific antibody-receptor fusion protein targeting human CD47xHER2（IMM2902) completed the first patient in (FPI).

On June 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that our newly developed ADCC-enhanced CTLA-4 antibody (IMM27M) completed the first patient enrollment and first dosing. The administration and the infusion process was smooth.